Khaled Ezzedine News Today

These data highlight the severe economic burden faced by patients with vitiligo compared to that of the general population, including mental health-related costs.

Substantial facial and total body repigmentation in patients with nonsegmental vitiligo was achieved in separate trials of povorcitinib and baricitinib plus phototherapy.

This new data from the phase 2b trial on povorcitinib could lead to developments in the dermatology space for vitiligo patients.